Rapid response to therapy of neurocutaneous melanosis with leptomeningeal melanoma.
Subbiah
Vivek
V
Wolff
Johannes E A
JE
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000008:administration & dosage; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000008:administration & dosage; D003606:Dacarbazine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D008545:Melanoma / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D008548:Melanosis / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D008577:Meningeal Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D020752:Neurocutaneous Syndromes / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000008:administration & dosage; D000077157:Sorafenib; D000077204:Temozolomide; D016896:Treatment Outcome
D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D003606:Dacarbazine; D003520:Cyclophosphamide; D000077157:Sorafenib; D000077204:Temozolomide